Post-transplant lymphoproliferative disorder (PTLD) is uncommonly of T cell origin, especially following BMT. We describe a 13-year-old boy with severe aplastic anemia (SAA) and no evidence of Fanconi's anemia who underwent BMT at 11 years of age using CY 10 mg/kg once daily i.v. on days ؊5, ؊4, antilymphocyte globulin (ALG) 30 mg/kg once daily i.v. on days ؊5ෂ؊3 and CsA from day ؊1 as conditioning. The BMT failed and he received a further peripheral blood stem cell transplant (PBSCT) 240 days after BMT. Conditioning was with CY 50 mg/kg once daily i.v. on days ؊5ෂ؊2, and ALG 15 mg/kg once daily i.v. on days ؊4ෂ؊2. GVHD prophylaxis included CsA and MTX. Engraftment was later confirmed by cytogenetic studies. Desquamation and ulcers of the oral mucosa and mouth angle developed in the 13th month post PBSCT. A buccal mucosa biopsy on day ؉524 revealed only plasmacytosis. Immunosuppressants were discontinued at that point. Generalized lymphadenopathy, prolonged fever (waxing and waning) and facial swelling developed in the 18th month post PBSCT. A neck lymph node biopsy on day ؉601 showed T cell lymphoma of diffuse large cell type with monoclonal TCR ␥-chain gene rearrangement. A FISH study showed that the malignant T cells were of recipient origin. EBV in situ hybridization was negative. He did not receive further treatment apart from discontinuation of immunosuppressants. He was followed up in our out-patient clinic and showed good performance 1170 days post PBSCT. We speculate that a different mechanism was operating in the pathogenesis of T cell lymphoma in this case. PTLD is the most common secondary malignancy after hematopoietic stem cell transplantation.
PTLD is the most common secondary malignancy after hematopoietic stem cell transplantation. 1 B cell PTLD makes up the majority of cases and is usually associated with EBV. 2 To our knowledge, there have been only three cases of T cell PTLD occurring after BMT. 3 We report a case of T cell PTLD occurring after BMT and PBSCT in a 13-year-old boy with SAA.
Case report
A 13-year-old boy with SAA received a BMT and PBSCT when he was 11 and 12 years old, respectively. He had had ecchymosis and easy bruising since 4 years of age with platelet count of around 19 ϫ 10 9 /l. He had no gross facial abnormalities, no bony defects or eye or renal anomalies. No skin hyperpigmentation or café-au-lait spots were noted. SAA was diagnosed on a bone marrow study. A mitomycin C test showed a 62% breakage rate, and a diepoxybutane stress test was non-reactive, thus excluding Fanconi's anemia. Multiple blood components were given thereafter. He began prednisolone therapy at 10 years of age and underwent BMT at 11 years of age from his HLA-identical sister. Conditioning comprised CY 10 mg/kg once daily i.v. on days Ϫ5, Ϫ4, and antilymphocyte globulin (ALG) 30 mg/kg once daily i.v. on days Ϫ5ෂϪ3. CsA was administered from day Ϫ1 for GVHD prophylaxis. Hemograms showed WBC 3ෂ4 ϫ 10 9 /l, Hb 7.5ෂ8.5 g/dl and platelet 20ෂ60 ϫ 10 9 /l before BMT. Graft failure was diagnosed on day ϩ17 by cytogenetic studies, and his hemograms remained at WBC 2ෂ3 ϫ 10 9 /l, Hb 6ෂ8.5 g/dl and platelet 20ෂ70 ϫ 10 9 /l thereafter until further PBSCT. He received PBSCT 240 days after BMT from the same donor when he was 12 years old. Conditioning comprised CY 50 mg/kg once daily i.v. on days Ϫ5ෂϪ2, and ALG 15 mg/kg once daily i.v. on days Ϫ4ෂϪ2. GVHD prophylaxis included CsA i.v. from day Ϫ1 (3 mg/kg once daily), MTX i.v. on day ϩ1 (15 mg/m 2 once daily), days ϩ3,ϩ6,ϩ11 (10 mg/m 2 once daily). PBSC which were mobilized with Filgrastim (10 g/kg once daily s.c.) were infused without manipulation. The cell dosage was 11.07 ϫ 10 8 nucleated cells/kg. On day ϩ17 the ANC was over 0.5 ϫ 10 9 /l. Full engraftment was confirmed on day ϩ18 by a peripheral blood cytogenetic study (46XX in 9/9 cells) confirmed in bone marrow (46XX 20/20 cells). The post-transplant course was uneventful and CsA was given orally with tapering. His hemograms remained at WBC 3ෂ5 ϫ 10 9 /l, Hb 10 g/dl and platelet 60ෂ70 ϫ 10 9 /l during follow-up. Unfortunately, desquamation and ulcers of the oral mucosa and mouth angle developed in the 13th month post-PBSCT. Prednisolone was added to the CsA because of the suspicion of chronic GVHD. However, the ulcers oozed persistently over the following days and Azathioprine was added in the 17th month post PBSCT, although the ulcers did not improve significantly. A buccal mucosal biopsy on day ϩ524 revealed polyclonal plasmacytosis with a lamina propria intensely infiltrated by actively proliferating, differentiated plasma cells. There was no evidence of GVHD. The immunosuppressants were all discontinued thereafter.
However, generalized bilateral lymphadenopathy of the cervical, axillary and inguinal areas, high fever (Ͼ39°C), facial swelling and a foreign body sensation during swallowing were noted in the 19th month post PBSCT. A retropharyngeal abscess was found on MRI. Broad-spectrum antibiotics were given for 2 weeks. The fever subsided 2 days after the antibiotics were commenced and facial swelling improved gradually. The retropharyngeal abscess had resolved on the follow-up MRI.
Fever again developed 2 days after discontinuing the antibiotics which did not respond when these were reintroduced. Bilateral cervical lymphadenopathy (multiple small lymph nodes estimated to be 1ෂ2 cm in diameter) was again noted, with swelling and tenderness. Blood cultures for bacteria, viruses, tuberculosis, and fungus were all negative. Titers of EBV-VCA IgM and IgG in serum were 1:10 negative and 1:10 240 positive, respectively. An anti-HIV test was negative. Neck lymph node biopsy was carried out on day ϩ601. Microscopically, there was partial effacement of the nodal architecture with residual lymphoid follicles and expansion of the subcapsular and medullary T zone. Infiltration by atypical large lymphoid cells with vesicular nuclei and moderate abundant cytoplasm was noted, with karyorrhexis, necrosis and histiocyte proliferation. Immunoperoxidase studies performed on formalin-fixed, paraffinembedded tissue revealed cells with positive staining with the monoclonal antibody UCHL-1 (a T cell marker), but CD20, 30, 68 and EBV in situ hybridization were all negative. PCR amplification of the TCR-␥ chain gene revealed a single sharp band of rearrangement, showing the monoclonal origin (Figure 1 ). The t(2,5) translocation was negative. A two-color FISH study showed XX 286 cells, XY 174 cells, X 93 cells, Y 44 cells and unstained 9 cells in 606 cells (Figure 2) . A concomitant bone marrow cytogenetic study showed 46 XX (13/13 cells).
After serial staging, the diagnosis was stage II T cell lymphoma (diffuse large cell type with TCR ␥-chain gene rearrangement) with bilateral cervical and mediastinal lymph node involvement. The patient did not receive further treatment for personal reasons. The fever subsided 20 days later with NSAIDs and the bilateral neck lymphadenopathy resolved 4 months later (7 months after discontinuing immunosuppressants). However, several neck lymph nodes sized 0.5ෂ1 cm have recently become evident (17 months after the T cell lymphoma was diagnosed) but there is no hepatosplenomegaly. The hemogram now /l. He is currently 1170 days post PBSCT, and is being closely followed-up.
Discussion
Patients who receive transplantation have a higher risk of secondary malignancies than do the general population. Lymphoid proliferations are the most frequent type. 4 The risk is greatest within the first year after transplantation. 5 Possible mechanisms for this include genetic predisposition, genetic damage resulting from chemotherapy or radiotherapy, immune deficiency associated with GVHD or immunosuppression and virus-association. Thus the majority of PTLDs are in allogeneic rather than autologous recipients probably due to the prolonged immunosuppression (delayed immune recovery of the donor immunocompetent cells, immunosuppressive therapy) and GVHD. 6 Some reports have pointed out that patients with primary diseases such as primary immune deficiency disease, leukemia and SAA have a high risk of developing secondary cancer.
1,2 Our case had SAA and received two transplants with a conditioning regimen of CY and ALG, prolonged usage of CsA and treatment with azathioprine, and he was a pediatric patient. Therefore, these risk factors might have contributed to his PTLD.
The manifestations of PTLD are non-specific. Patients usually present with an infectious mononucleosis-like syndrome with fever, lymphadenopathy, hepatosplenomegaly, skin rash and occasional pulmonary, renal and central ner- vous system involvement. Our case had a prolonged fever of unknown origin, hepatosplenomegaly and bilateral neck lymphadenopathy. We finally confirmed the diagnosis of T cell lymphoma after it was proven by a neck lymph node biopsy. Therefore, we should always keep in mind the possibility of PTLD in the event of non-specific symptoms and signs.
Most cases of PTLD in solid organ transplant patients are of recipient origin, and usually develop in or near the grafted organ. 7 However, PTLD in BMT recipients is typically of donor origin. [8] [9] [10] The mechanism is unknown, but the predominant donor lymphoid cell proliferation might be the cause. In Zutter et al's report, 3 three cases of T cell PTLD after BMT were of donor origin, undetermined, or of recipient origin (Table 1) , but the FISH study in our case revealed that about one-third of the formative cells were of recipient origin and two-thirds of the cells were of donor origin. It seems that the recipient cells may have been malignant and grown back. After immunosuppressive agents were discontinued, the GVL effect may have eradicated the recipient malignant clone.
B cell PTLDs constitute the majority of cases. They are usually associated with T cell dysfunction and the presence of EBV. 2 It is believed that transformed B cells with EBV genomic DNA integration escape from T cell immune surveillance and proliferate, forming B cell PTLD thereafter. On the other hand, only 12-14% of PTLD after organ Bone Marrow Transplantation transplantation is of T cell origin. 11 The role of EBV in T cell PTLD remains unclear although EBV has been demonstrated in the small subset of T-lineage lymphomas occurring among patients with chronic EBV syndrome. 12 It has been postulated that viral infection may play an important role in T cell PTLD similar to EBV in B cell PTLD. However, in the cases of T cell PTLD after BMT in Zutter et al's report 3 and those after organ transplantation in Hanson et al's report, 13 there was no evidence of viral infection including EBV, HTLV-I, HTLV-II, HIV, HHV-6 and HHV-8. There was also no evidence of viral infection in our case, including HIV and HTLV-1. The serology of EBV titer was high with 1:10 240 EBV-VCA IgG positivity in serum. However, the EBV in situ hybridization was negative. We speculate that EBV infection was not the leading cause of T cell PTLD in this case, but the association between T cell PTLD and EBV remains unclear.
The mean interval from organ transplant to PTLD is 210 days.
11 In Cohen's review, 14 the mean interval from BMT to the development of B cell PTLD was 5 months. By comparison, the mean interval in the three cases of T cell PTLD after BMT was 7 months, longer than that in B cell PTLD. The interval from PBSCT to the development of T cell PTLD in the present case was 20 months. It seems that development of T cell PTLD occurs later than B cell PTLD after BMT. We postulate that EBV is usually associated with B cell PTLD and EBV should greatly proliferate under immunosuppression. Thus, the EBV transformed B cells become B cell PTLD faster than T cell PTLD which is not obviously infected by virus.
No standard approach for therapy in PTLD has been clearly established, but approaches have been as follows: reduction or discontinuation of immunosuppressive therapy, chemotherapy, surgical resection of limited disease, ␣-interferon, IVIG, ganciclovir, B cell-specific monoclonal antibody, adoptive immunotherapy and cellular therapy.
Armitage et al's report 15 revealed that the mean survival of T cell PTLD after solid organ transplantation was 5 weeks after the lymphoma was noted, although survival with T cell PTLD after BMT (Table 1 ) was 28, 6 months and 11 days. 3 Our patient did not receive any intensive therapy but rather discontinued his immunosuppressive therapy. He is currently well 19 months after the diagnosis of recipient-origin lymphoma because of a GVL effect following cessation of immunosuppression. His clinical course will be monitored closely.
In summary, T cell PTLDs are uncommon especially after BMT. The etiology remains unclear. There may be different mechanisms in operation in T cell PTLD. Although T cell PTLD after BMT develops later than does B cell PTLD, the outcome is worse than that of B cell PTLD. However, the recipient origin T cell PTLD in our case may have had a better outcome due to the GVL effect. Therefore, the optimal treatment should be defined for the future. 
